Advertisement
Advertisement
ACRS
Aclaris Therapeutics, Inc.
3.55
USDSponsored
+0.04
+1.14%
Mar 13, 16:00 UTC -4
Closed
After-Market
3.53
-0.02
-0.45%
ACRS Earnings Reports
Positive Surprise Ratio
ACRS beat 28 of 41 last estimates.
68%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.22M
/-$0.16
Implied change from Q4 25 (Revenue/ EPS)
-5.54%
/--
Implied change from Q1 25 (Revenue/ EPS)
-15.93%
/+33.33%
Aclaris Therapeutics, Inc. earnings per share and revenue
On Jan 06, 2026, ACRS reported earnings of -0.16 USD per share (EPS) for Q4 25, missing the estimate of -0.15 USD, resulting in a -4.58% surprise. Revenue reached 1.29 million, compared to an expected 1.98 million, with a -34.50% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.16 USD, with revenue projected to reach 1.22 million USD, implying an increase of 0.00% EPS, and decrease of -5.54% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.45
Actual
-$0.42
Surprise
+6.77%
Esperion Therapeutics, Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.24
Actual
$0.22
Surprise
-10.46%
Nektar Therapeutics
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.52
Actual
-$1.78
Surprise
+29.47%
Zevra Therapeutics, Inc. Common Stock
Report Date
Mar 09, 2026 For Q4 25
Estimate
$0.05
Actual
$0.21
Surprise
+311.76%
SIGA Technologies Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
-Actual
-$0.08
Surprise
-
Nature's Sunshine Products Inc.
Report Date
Mar 10, 2026 For Q4 25
Estimate
$0.19
Actual
$0.30
Surprise
+54.80%
Century Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.25
Surprise
+13.49%
Corbus Pharmaceuticals Holdings, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$1.60
Actual
-$1.25
Surprise
+22.24%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.81
Actual
-$0.51
Surprise
+37.05%
Champions Oncology, Inc.
Report Date
Mar 12, 2026 For Q3 26
Estimate
$0.09
Actual
-$0.02
Surprise
-121.79%
FAQ
What were Aclaris Therapeutics, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Aclaris Therapeutics, Inc. reported EPS of -$0.16, missing estimates by -4.58%, and revenue of $1.29M, -34.5% below expectations.
How did the market react to Aclaris Therapeutics, Inc.'s Q4 2025 earnings?
The stock price moved -- 0%, changed from $2.65 before the earnings release to $2.65 the day after.
When is Aclaris Therapeutics, Inc. expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Aclaris Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Aclaris Therapeutics, Inc. is expected to report EPS of -$0.16 and revenue of $1.22M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement